Scarborough, MENCT06333262Now EnrollingIRB Ready

Chronic Lymphocytic Leukemia Clinical Trial in Scarborough, ME

Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in Scarborough. Study-provided care at no cost to qualified participants.

Sponsored by Inhye Ahn

Quick Self-Assessment

See if you qualify for this Scarborough location

Preparing your pre-screening questions…

Expert Care in Scarborough

Access chronic lymphocytic leukemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related chronic lymphocytic leukemia treatment provided free

Apply for This Scarborough Location

Check if you qualify for this chronic lymphocytic leukemia clinical trial in Scarborough, ME

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Scarborough

    Convenient for ME residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Scarborough site if eligible
  4. 4Begin participation

About This Chronic Lymphocytic Leukemia Study in Scarborough

This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).

Sponsor: Inhye Ahn

Who Can Participate

Inclusion Criteria

Meet 2018 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines for the diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Presence of measurable disease (absolute lymphocyte count \> 5,000/µL, palpable or measurable lymph nodes ≥1.5cm on imaging, or bone marrow involvement of CLL ≥ 30%).
No prior systemic therapy for CLL or SLL.
Currently have an indication for treatment as defined by the following 2018 IWCLL guidelines
Age ≥ 18 years
Eastern Cooperative Oncology Group performance status ≤ 2
Adequate organ and bone marrow function as defined by the study protocol
Ability to take oral medications.
Ability to understand and the willingness to sign a written informed consent document. Key

Exclusion Criteria

Known or suspected Richter's transformation or known central nervous system involvement.
History of bleeding disorders
History of stroke or intracranial hemorrhage within 6 months of starting study therapy.
Significant cardiovascular disease such as uncontrolled arrhythmia, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction \< 40% by any methods in the 12 months prior to study therapy.
History of other malignancies with life expectancy of \< 2 years.
Receiving any other investigational agents.
Concurrent systemic immunosuppression \< 28 days of study therapy or administration of \> 20 mg of prednisone or equivalent daily \< 7 days of study therapy.
Vaccinated with live vaccine within 4 weeks of starting study therapy.
Major surgery within 4 weeks of starting study therapy.
Ongoing or recent infection requiring intravenous antimicrobials at time of screening. Prophylactic antibiotics are allowed if there is no evidence of active infection and the antibiotics is not included on the list of the prohibited medications.
Patients who have tested positive for HIV are excluded due to potential drug-drug interactions between anti-retroviral medications and pirtobrutinib and risk of opportunistic infections with both HIV and irreversible BTK inhibitors. For patients with unknown HIV status, HIV testing will be performed at Screening and result should be negative for enrollment.
Active human T cell leukemia virus infection or active hepatitis B or C virus infection
Known active cytomegalovirus infection
Pregnancy, lactation or plan to breastfeed during the study or within 6 months of the last dose of study treatment.
Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the study drug
Active uncontrolled auto-immune cytopenia.
Significant co-morbid condition or disease.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Scarborough?

Yes, this clinical trial (NCT06333262) has an active research site in Scarborough, ME that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Chronic Lymphocytic Leukemia Treatment Options in Scarborough, ME

If you're searching for chronic lymphocytic leukemia treatment options in Scarborough, ME, this clinical trial (NCT06333262) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Scarborough research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all chronic lymphocytic leukemia clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Scarborough, ME

See all leukemia clinical trials recruiting in Scarborough — not just this study.

Browse Leukemia Trials in Scarborough →

Browse More Trials by Condition

Leukemia TrialsChronic Lymphocytic Leukemia TrialsHeart Attack TrialsPulmonary Hypertension TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Scarborough?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Scarborough, ME